Defining the role of MRP-mediated efflux and glutathione in detoxification of oxaliplatin

Pharmazie

Volumn 68, Issue 7, 2013, Pages 622-627

  Mohn, C ^a   Hacker H G ^a   Hilger, R A ^b   Gutschow M ^a   Jaehde, U ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GLUTATHIONE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; OXALIPLATIN;

AMINO ACID SYNTHESIS; ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DRUG DETOXIFICATION; HUMAN; HUMAN CELL; IN VITRO STUDY;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DNA, NEOPLASM; GLUTATHIONE; HUMANS; METABOLIC DETOXICATION, DRUG; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANOPLATINUM COMPOUNDS; PLATINUM;

EID: 84882942352     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2013.6523     Document Type: Article

References (38)

1. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR (1988) Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48: 589-601.
2. Anderson ME (1998) Glutathione: An overview of biosynthesis and modulation. Chem Biol Interact 111-112: 1-14.
3. Arnould S, Hennebelle I, Canal P, Bugat R, Guichard S (2003) Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J Cancer 39: 112-119.
4. Ballatori N, Krance SM, Notenboom S, Shi S, Tieu K, Hammond CL (2009) Glutathione dysregulation and the etiology and progression of human diseases. Biol Chem 390: 191-214.
5. Benedetti BT, Peterson EJ, Kabolizadeh P, Martinez A, Kipping R, Farrell NP (2011) Effects of noncovalent platinum drug-protein interactions on drug efficacy: Use of fluorescent conjugates as probes for drug metabolism. Mol Pharm 8: 940-948.
6. Boubakari, Bracht K, Neumann C, Grunert R, Bednarski PJ (2004) No correlation between GSH levels in human cancer cell lines and the cell growth inhibitory activities of platinum diamine complexes. Arch Pharm (Weinheim) 337: 668-671.
7. Bracht K, Boubakari, Grünert R, Bednarski PJ (2006) Correlations between the activities of 19 anti-tumor agents and the intracellular glutathione concentrations in a panel of 14 human cancer cell lines: Comparisons with the National Cancer Institute data. Anticancer Drugs 17: 41-51.
8. Bracht K, Liebeke M, Ritter CA, Grünert R, Bednarski PJ (2007) Correlations between the activities of 19 standard anticancer agents, antioxidative enzyme activities and the expression ofATP-binding cassette transporters: Comparison with the National Cancer Institute data. Anticancer Drugs 18: 389-404.
9. Burger H, Loos WJ, Eechoute K, Verweij J, Mathijssen RH, Wiemer EA (2011) Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist Update 14: 22-34.
10. Chen G, Hutter KJ, Zeller WJ (1995) Positive correlation between cellular glutathione and acquired cisplatin resistance in human ovarian cancer cells. Cell Biol Toxicol 11: 273-281.
11. Chen HH, Kuo MT (2010) Role of glutathione in the regulation of cisplatin resistance in cancer chemotherapy. Met Based Drugs 2010: 430939.
12. Cnubben NH,Wortelboer HM, van Zanden JJ, Rietjens IM, van Bladeren PJ (2005) Metabolism of ATP-binding cassette drug transporter inhibitors: Complicating factor for multidrug resistance. Expert Opin Drug Metab Toxicol 1: 219-232.
13. El-Akawi Z, Abu-Hadid M, Perez R, Glavy J, Zdanowicz J, Creaven PJ, Pendyala L (1996) Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells. Cancer Lett 105: 5-14.
14. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G (2012) Molecular mechanisms of cisplatin resistance. Oncogene 31: 1869-1883.
15. Goto S, Yoshida K, Morikawa T, Urata Y, Suzuki K, Kondo T (1995) Augmentation of transport for cisplatin-glutathione adduct in cisplatinresistant cancer cells. Cancer Res 55: 4297-4301.
16. Gourdier I, Crabbe L, Andreau K, Pau B, Kroemer G (2004) Oxaliplatininduced mitochondrial apoptotic response of colon carcinoma cells does not require nuclear DNA. Oncogene 23: 7449-7457.
17. Hall MD, Okabe M, Shen DW, Liang XJ, Gottesman MM (2008) The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol 48: 495-535.
18. Hector S, Nava ME, Clark K, Murphy M, Pendyala L (2007) Characterization of a clonal isolate of an oxaliplatin resistant ovarian carcinoma cell line A2780/C10. Cancer Lett 245: 195-204.
19. Ishikawa T, Ali-Osman F (1993) Glutathione-associated cisdiamminedichloroplatinum (II) metabolism and ATP-dependent efflux from leukemia cells. J Biol Chem 268: 20116-20125.
20. Jedlitschky G, Hoffmann U, Kroemer HK (2006) Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition. Expert Opin Drug Metab Toxicol 2: 351-366.
21. JohnsonSW, Laub PB, Beesley JS, Ozols RF, Hamilton TC (1997) Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res 57: 850-856.
22. Kalayda GV,Wagner CH, Buss I, Reedijk J, Jaehde U (2008) Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells. BMC Cancer 8: 175.
23. Kasherman Y, Sturup S, Gibson D (2009) Is glutathione the major cellular target of cisplatin? A study of the interactions of cisplatin with cancer cell extracts. J Med Chem 52: 4319-4328.
24. Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7: 573-584.
25. Kloft C, Appelius H, Siegert W, Schunack W, Jaehde U (1999) Determination of platinum complexes in clinical samples by a rapid flameless atomic absorption spectrometry assay. Ther Drug Monit 21: 631-637.
26. Leitner HM, Kachadourian R, Day BJ (2007) Harnessing drug resistance: UsingABCtransporter proteins to target cancer cells. Biochem Pharmacol 74: 1677-1685.
27. Lewicki K, Marchand S, Matoub L, Lulek J, Coulon J, Leroy P (2006) Development of a fluorescence-based microtiter plate method for the measurement of glutathione in yeast. Talanta 70: 876-882.
28. Leyers S, Häcker HG, Wiendlocha J, Gütschow M, Wiese M (2008) A 4-aminobenzoic acid derivative as novel lead for selective inhibitors of multidrug resistance-associated proteins. Bioorg Med Chem Lett 18: 4761-4763.
29. Liu Z, Qiu M, Tang QL, Liu M, Lang N, Bi F (2010) Establishment and biological characteristics of oxaliplatin-resistant human colon cancer cell lines. Chin J Cancer 29: 661-667.
30. Luo FR, Yen TY, Wyrick SD, Chaney SG (1999) High-performance liquid chromatographic separation of the biotransformation products of oxaliplatin. J Chromatogr B Biomed Sci Appl 724: 345-356.
31. Mandic A, Hansson J, Linder S, ShoshanMC(2003) Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem 278: 9100-9106.
32. Meijer C, Mulder NH, Timmer-Bosscha H, Sluiter WJ, Meersma GJ, de Vries EG (1992) Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res 52: 6885-6889.
33. Mieyal JJ, Gallogly MM, Qanungo S, Sabens EA, Shelton MD (2008) Molecular mechanisms and clinical implications of reversible protein S-glutathionylation. Antioxid Redox Signal 10: 1941-1988.
34. MohnC, KalaydaGV, HäckerHG,GütschowM, Metzger S, JaehdeU(2010) Contribution of glutathione and MRP-mediated efflux to intracellular oxaliplatin accumulation. Int J Clin Pharmacol Ther 48: 445-447.
35. Noma B, Sasaki T, Fujimoto Y, Serikawa M, Kobayashi K, Inoue M, Itsuki H, Kamigaki M, Minami T, Chayama K (2008) Expression of multidrug resistance-associated protein 2 is involved in chemotherapy resistance in human pancreatic cancer. Int J Oncol 33: 1187-1194.
36. Pendyala L, Perez R, Weinstein A, Zdanowicz J, Creaven PJ (1997) Effect of glutathione depletion on the cytotoxicity of cisplatin and iproplatin in a human melanoma cell line. Cancer Chemother Pharmacol 40: 38-44.
37. Stewart DJ (2007) Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 63: 12-31.
38. Wortelboer HM, Balvers MG, Usta M, van Bladeren PJ, CnubbenNH(2008) Glutathione-dependent interaction of heavy metal compounds with multidrug resistance proteins MRP1 and MRP2. Environ Toxicol Pharmacol 26: 102-108.